Bromocriptine treatment of neuroleptic malignant syndrome.

Abstract

Five patients with neuroleptic malignant syndrome were treated with bromocriptine mesylate 7.5-45 mg/day in three divided doses for at least 10 days. Response to therapy was assessed by monitoring vital signs and serum creatine kinase (CK) levels. In addition, a disability score was determined using a scale based on variables assessed on neurologic examinations. In all five patients, significant improvement was noted 24-72 hours after initiation of bromocriptine treatment and was accompanied in four patients by a rapid drop in serum CK levels. Resolution of confusion and mutism was noted within 24-48 hours after treatment. Normalization of vital signs occurred within 48 hours to 4 days, and resolution of extrapyramidal rigidity occurred within 1 week. In two patients, early discontinuation of bromocriptine resulted in relapse of neuroleptic malignant syndrome, which responded to reinstitution of the drug. The results suggest a therapeutic role for bromocriptine in the treatment of neuroleptic malignant syndrome.

• Authors: S Dhib-Jalbut, R Hesselbrock, M M Mouradian, E D Means
• Journal: The Journal of clinical psychiatry (J Clin Psychiatry) Vol. 48 Issue 2 Pg. 69-73 (Feb 1987) ISSN: 0160-6689 [Print] United States
• PMID: 3804991 (Publication Type: Case Reports, Journal Article)

Chemical References

• Bromocriptine
• Creatine Kinase

Topics

• Adolescent
• Adult
• Bromocriptine (administration & dosage, therapeutic use)
• Creatine Kinase (blood)
• Drug Evaluation
• Female
• Humans
• Male
• Middle Aged
• Neuroleptic Malignant Syndrome (blood, drug therapy, physiopathology)
• Neurologic Examination
• Time Factors